Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$61.4MCash on Hand
26.6mo Cash Runway
Follow UNCY by emailGet an email when UNCY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about UNCY, unsubscribe in one click. Privacy
💊 Upcoming FDA Decisions
PDUFA Date
Drug
Indication
Type
PoA
2027-03-25
oxylanthanum carbonate (OLC)
NDA
59%
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
📣 What UNCY Says Is Next
second half of 2027 · “As of June 30, 2026, unaudited cash, cash equivalents and marketable securities totaled $61.4 million, supporting continued OLC commercial launch preparation and an expected cash runway into the second half of 2027.”
Company press release, Sep 29, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 16, 2026 ·
Earnings Reported Q3 2026 net loss of $(7.0) million, or $(0.25) per share, versus $(6.0) million a year earlier, citing higher commercial launch expenses. Cash, equivalents and marketable securities were about $59 million, with runway beyond 2027. FDA accepted the OLC NDA resubmission with a PDUFA date of March 25, 2027. Form 8-K · SEC filing · Press release
Sep 29, 2026 ·
Regulatory Unicycive resubmitted its NDA for oxylanthanum carbonate with CMC data from a new drug product manufacturing vendor, and expects FDA acceptance within 30 days and a new PDUFA date six months after resubmission. Cash was $61.4 million at June 30, 2026, with runway into 2H 2027. Form 8-K · SEC filing · Press release
Sep 28, 2026 ·
Legal A securities class action was filed on September 3, 2026 in the U.S. District Court for the Northern District of California against the company and certain officers. It alleges federal securities law violations tied to public statements about the new drug application for oxylanthanum carbonate phosphate binder. Form 8-K · SEC filing
Aug 12, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 12, 2026 ·
Earnings Reported Q2 2026 net loss of $(1.7) million, or $(0.06) per share, versus $(6.5) million a year earlier, with cash and marketable securities of $61.4 million and runway into 2027. Received a June CRL citing third-party manufacturing deficiencies; FDA has assigned a facility inspection. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2024 · Phase 2 · Results Expected · A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
UNCY holds $61.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $6.9M/quarter from operations,
an estimated runway of 26.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:47 · Elevated
Cash runway 27 months
ATM program on file since Jun 2026 +15
Shelf registration (S-3, Jun 2026) +10
Share count +36% in a year +14
FDA decision in 128 days +8
Recent financing filings on SEC EDGAR:
Jun 5, 2026 · Shelf registration with ATM program, up to $50M · S-3
Share count 29,184,509 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for UNCY and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.